Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts
E Conte, E Gili, E Fagone, M Fruciano… - European Journal of …, 2014 - Elsevier
Pirfenidone is an orally active small molecule that has been shown to inhibit the progression
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …
of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis. Although …
Pirfenidone: molecular mechanisms and potential clinical applications in lung disease
SM Ruwanpura, BJ Thomas… - American journal of …, 2020 - atsjournals.org
Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …
[HTML][HTML] Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation
TN Vu, X Chen, HD Foda, GC Smaldone… - Respiratory …, 2019 - Springer
Background Idiopathic pulmonary fibrosis (IPF) pathogenesis involves multiple pathways,
and combined antifibrotic therapy is needed for future IPF therapy. Inhaled interferon-γ (IFN …
and combined antifibrotic therapy is needed for future IPF therapy. Inhaled interferon-γ (IFN …
[HTML][HTML] Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
J Jin, S Togo, K Kadoya, M Tulafu, Y Namba, M Iwai… - Respiratory …, 2019 - Springer
Background Pirfenidone, an antifibrotic agent used for the treatment of idiopathic pulmonary
fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in …
fibrosis (IPF), functions by inhibiting myofibroblast differentiation, which is involved in …
[HTML][HTML] Anti-fibrotic effects of pirfenidone and rapamycin in primary IPF fibroblasts and human alveolar epithelial cells
M Molina-Molina, C Machahua-Huamani… - BMC pulmonary …, 2018 - Springer
Background Pirfenidone, a pleiotropic anti-fibrotic treatment, has been shown to slow down
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
disease progression of idiopathic pulmonary fibrosis (IPF), a fatal and devastating lung …
[HTML][HTML] Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells
K Hisatomi, H Mukae, N Sakamoto, Y Ishimatsu… - BMC Pulmonary …, 2012 - Springer
Background Pirfenidone is a novel anti-fibrotic and anti-inflammatory agent that inhibits the
progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis …
progression of fibrosis in animal models and in patients with idiopathic pulmonary fibrosis …
[HTML][HTML] Pirfenidone alleviates pulmonary fibrosis in vitro and in vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3 signaling pathways
Q Lv, J Wang, C Xu, X Huang, Z Ruan, Y Dai - Molecular Medicine, 2020 - Springer
Background Pirfenidone (PFD) is effective for pulmonary fibrosis (PF), but its action
mechanism has not been fully explained. This study explored the signaling pathways …
mechanism has not been fully explained. This study explored the signaling pathways …
Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
H Oku, T Shimizu, T Kawabata, M Nagira, I Hikita… - European journal of …, 2008 - Elsevier
Pirfenidone, a broad-spectrum antifibrotic agent, is known to have efficacy in certain fibrotic
disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We …
disease models, and is under clinical trials in patients with idiopathic pulmonary fibrosis. We …
[HTML][HTML] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis
ST Lehtonen, A Veijola, H Karvonen… - Respiratory …, 2016 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor
prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently …
prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently …
Antifibrotic activities of pirfenidone in animal models
CJ Schaefer, DW Ruhrmund, L Pan… - European …, 2011 - Eur Respiratory Soc
Pirfenidone is an orally active small molecule that has recently been evaluated in large
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …
clinical trials for the treatment of idiopathic pulmonary fibrosis, a fatal disease in which the …
相关搜索
- fibrogenic activity pirfenidone on proliferation
- myofibroblast differentiation pirfenidone on proliferation
- fibrogenic activity myofibroblast differentiation
- lung fibroblasts pirfenidone on proliferation
- fibrogenic activity lung fibroblasts
- lung fibroblasts myofibroblast differentiation
- fibrogenic activity tgf β
- tgf β myofibroblast differentiation
- tgf β pirfenidone on proliferation
- lung fibroblasts tgf β
- properties of fibroblasts pirfenidone and nintedanib
- fibrogenic activity effect of pirfenidone
- myofibroblast differentiation effect of pirfenidone
- lung fibroblasts effect of pirfenidone
- tgf β effect of pirfenidone